Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2022 Dec 28;32(5):558–566. doi: 10.1002/pds.5579

Table 2:

Baseline characteristics of population

Characteristic n=859
Age (median [IQR]) 68.53 [58.76, 74.68]

Gender, M (%) 822 (95.7)

Race (%)

 White 495 (57.6)

 Black or African American 239 (27.8)

 Native Hawaiian or other Pacific Islander 5 ( 0.6)

 Asian 4 ( 0.5)

 Unknown 116 (13.5)

Annotated as having diagnosis of multiple myeloma (%) 702 (81.7)
Annotated as initiating treatment in VA (%)

 Yes 500 (58.2)

 No 191 (22.2)

 Not multiple myeloma 157 (18.3)

 Cannot tell 7 ( 0.8)

 Info not explicit in notes 4 ( 0.5)

Year of initial treatment (%)

 ≤ 2006 149 (17.3)

 2007–2014 163 (19.0)
 2015–2021 188 (21.9)

 Not initially treated in VA, not true myeloma, or date not recorded 359 (41.8)